[go: up one dir, main page]

MA51204B1 - Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique - Google Patents

Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique

Info

Publication number
MA51204B1
MA51204B1 MA51204A MA51204A MA51204B1 MA 51204 B1 MA51204 B1 MA 51204B1 MA 51204 A MA51204 A MA 51204A MA 51204 A MA51204 A MA 51204A MA 51204 B1 MA51204 B1 MA 51204B1
Authority
MA
Morocco
Prior art keywords
plasma kallikrein
kallikrein inhibitor
pharmaceutical forms
compound
formula
Prior art date
Application number
MA51204A
Other languages
English (en)
Other versions
MA51204A (fr
Inventor
John Herman Collett
Gary Paul Cook
Jamie Joseph Farrar
Michael John Frodsham
Michael Bryan Roe
Richard Simon Todd
Robert Neil Ward
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of MA51204A publication Critical patent/MA51204A/fr
Publication of MA51204B1 publication Critical patent/MA51204B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formes pharmaceutiques solides orales comprenant un inhibiteur de la kallicréine plasmatique, en particulier une forme solide (forme1) du composé de formule a. L'invention concerne également des procédés de préparation de formes pharmaceutiques solides orales comprenant le composé de formule a en utilisant la forme 1 du composé de formule a.
MA51204A 2017-12-21 2018-11-28 Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique MA51204B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1721515.3A GB201721515D0 (en) 2017-12-21 2017-12-21 Dosage forms comprising a plasma kallikrein inhibtor
PCT/GB2018/053443 WO2019106361A1 (fr) 2017-11-29 2018-11-28 Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique

Publications (2)

Publication Number Publication Date
MA51204A MA51204A (fr) 2020-10-07
MA51204B1 true MA51204B1 (fr) 2022-02-28

Family

ID=61131610

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51204A MA51204B1 (fr) 2017-12-21 2018-11-28 Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique

Country Status (10)

Country Link
EP (1) EP3716952B1 (fr)
KR (1) KR102696615B1 (fr)
CN (1) CN111432803B (fr)
AU (1) AU2018376817B2 (fr)
BR (1) BR112020010154A2 (fr)
CA (1) CA3083856A1 (fr)
GB (1) GB201721515D0 (fr)
MA (1) MA51204B1 (fr)
TW (1) TWI800567B (fr)
WO (1) WO2019106361A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910125D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
WO2021175290A1 (fr) * 2020-03-04 2021-09-10 南京明德新药研发有限公司 Composé hétérocyclique
CN112089710B (zh) * 2020-08-07 2022-04-01 郑州大学 4-羟基异亮氨酸在制备抗肿瘤药物中的应用
TW202228686A (zh) * 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療
US20230381162A1 (en) 2020-10-23 2023-11-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
JP2022069377A (ja) * 2020-10-23 2022-05-11 カルビスタ・ファーマシューティカルズ・リミテッド 血管性浮腫の処置
JP2024505596A (ja) * 2021-02-09 2024-02-06 カルビスタ・ファーマシューティカルズ・リミテッド 遺伝性血管性浮腫の治療
WO2023144030A1 (fr) 2022-01-31 2023-08-03 Oxurion NV Thérapie par inhibiteur de la kallicréine plasmatique pour une sensibilisation aux anti-vegf
LT4288036T (lt) 2022-04-27 2024-09-25 Kalvista Pharmaceuticals Limited Farmacinės plazmos kalikreino inhibitoriaus formos
EP4622642A1 (fr) * 2022-11-22 2025-10-01 Rezolute, Inc. Formes posologiques solides d'un inhibiteur de la kallicréine plasmatique
WO2024180100A1 (fr) 2023-02-27 2024-09-06 Kalvista Pharmaceuticals Limited Nouvelle forme solide d'un inhibiteur de la kallicréine plasmatique
WO2025172692A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat à administrer par voie orale pour le traitement d'une attaque d'angioedème héréditaire
WO2025172693A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat oral pour le traitement d'un épisode d'angio-œdème héréditaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
WO2015022546A1 (fr) * 2013-08-14 2015-02-19 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
PT3113772T (pt) * 2014-03-07 2020-12-15 Biocryst Pharm Inc Pirazois substituídos por trifluorometilo como inibidores de calicreína plasmática humana
GB201421085D0 (en) * 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) * 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421088D0 (en) * 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors

Also Published As

Publication number Publication date
EP3716952B1 (fr) 2022-01-05
AU2018376817A1 (en) 2020-06-04
CN111432803B (zh) 2022-08-26
KR102696615B1 (ko) 2024-08-19
KR20200093553A (ko) 2020-08-05
WO2019106361A1 (fr) 2019-06-06
TW201924682A (zh) 2019-07-01
CA3083856A1 (fr) 2019-06-06
TWI800567B (zh) 2023-05-01
AU2018376817B2 (en) 2024-02-15
BR112020010154A2 (pt) 2020-11-10
MA51204A (fr) 2020-10-07
GB201721515D0 (en) 2018-02-07
EP3716952A1 (fr) 2020-10-07
CN111432803A (zh) 2020-07-17

Similar Documents

Publication Publication Date Title
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
EA200970156A1 (ru) Пиридизиноновые производные
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA32787B1 (fr) Peptides antiviraux therapeutiques
MA30766B1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
MY151295A (en) Pyrimidyl indoline compound
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
FR2983409B1 (fr) Comprime susceptible de lutter contre le detournement par voie injectable
EA201490222A1 (ru) Комбинированные составы на основе дарунавира
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
AR058085A1 (es) Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2. composiciones farmaceuticas.
MA32275B1 (fr) Preparations orales et injectables de composes de tetracycline
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS